Crinetics Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Paltusotine is an oral selective nonpeptide somatostatin receptor type 2 agonists designed for the treatment of acromegaly and neuroendocrine tumors. CRN04777 is Co.'s investigational, oral, nonpeptide somatostatin receptor type 5 agonist designed for the treatment of congenital hyperinsulinism. CRN04894 is Co.'s investigational, oral, nonpeptide product candidate designed to antagonize adrenocorticotrophic hormone, or ACTH, intended for the treatment of diseases caused by excess ACTH. We show 24 historical shares outstanding datapoints in our CRNX shares outstanding history coverage, used to compute CRNX market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing CRNX market cap history over the course of time is important for investors
interested in comparing CRNX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of CRNX versus a peer is one thing; comparing
CRNX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like CRNX can fluctuate over the course of history.
With this page we aim to empower investors researching CRNX by allowing them to research the CRNX market cap history. |
Free CRNX Email Alerts:
Video: The Importance of Market Cap
